Anebulo Q1 FY2024 net loss $2.5M; FDA positive on Phase 3 path for ANEB-001

Anebulo Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.10

Net loss of $2.5M ($0.10/sh) vs $2.6M ($0.11/sh) in prior year quarter; operating expenses $2.5M.
Cash $8.5M as of Sep 30; secured credit facility of up to $10M from existing investors.
FDA Type B meeting: single ED study plus larger THC challenge may suffice for NDA for ANEB-001.
Richie Cunningham appointed CEO and Board member; Bimal Shah joined Board; Phase 3 targeted H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Anebulo Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income $2.5 million, or $(0.10) per share, EPS $(0.10) per share.

Period: three months ended September 30, 2023
Net income: $2.5 million, or $(0.10) per share
EPS: $(0.10) per share
Result: reported results

Exact text from the filing

Net loss in the first quarter of fiscal 2024 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.6 million, or $(0.11) per share, in the first quarter of fiscal 2023.

View on SEC.gov

Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.